These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

214 related items for PubMed ID: 33579185

  • 1. Discovery of vanoxerine dihydrochloride as a CDK2/4/6 triple-inhibitor for the treatment of human hepatocellular carcinoma.
    Zhu Y, Ke KB, Xia ZK, Li HJ, Su R, Dong C, Zhou FM, Wang L, Chen R, Wu SG, Zhao H, Gu P, Leung KS, Wong MH, Lu G, Zhang JY, Jiang BH, Qiu JG, Shi XN, Lin MC.
    Mol Med; 2021 Feb 12; 27(1):15. PubMed ID: 33579185
    [Abstract] [Full Text] [Related]

  • 2. In Silico Identification and In Vitro and In Vivo Validation of Anti-Psychotic Drug Fluspirilene as a Potential CDK2 Inhibitor and a Candidate Anti-Cancer Drug.
    Shi XN, Li H, Yao H, Liu X, Li L, Leung KS, Kung HF, Lu D, Wong MH, Lin MC.
    PLoS One; 2015 Feb 12; 10(7):e0132072. PubMed ID: 26147897
    [Abstract] [Full Text] [Related]

  • 3. Water extract of Hedyotis Diffusa Willd suppresses proliferation of human HepG2 cells and potentiates the anticancer efficacy of low-dose 5-fluorouracil by inhibiting the CDK2-E2F1 pathway.
    Chen XZ, Cao ZY, Chen TS, Zhang YQ, Liu ZZ, Su YT, Liao LM, Du J.
    Oncol Rep; 2012 Aug 12; 28(2):742-8. PubMed ID: 22641337
    [Abstract] [Full Text] [Related]

  • 4. Predictors of ribociclib-mediated antitumour effects in native and sorafenib-resistant human hepatocellular carcinoma cells.
    Reiter FP, Denk G, Ziesch A, Ofner A, Wimmer R, Hohenester S, Schiergens TS, Spampatti M, Ye L, Itzel T, Munker S, Teufel A, Gerbes AL, Mayerle J, De Toni EN.
    Cell Oncol (Dordr); 2019 Oct 12; 42(5):705-715. PubMed ID: 31250364
    [Abstract] [Full Text] [Related]

  • 5. A novel anticancer agent, SKLB70359, inhibits human hepatic carcinoma cells proliferation via G0/G1 cell cycle arrest and apoptosis induction.
    Dai XY, Zeng XX, Peng F, Han YY, Lin HJ, Xu YZ, Zhou T, Xie G, Deng Y, Mao YQ, Yu LT, Yang L, Zhao YL.
    Cell Physiol Biochem; 2012 Oct 12; 29(1-2):281-90. PubMed ID: 22415097
    [Abstract] [Full Text] [Related]

  • 6. Xylocydine, a novel Cdk inhibitor, is an effective inducer of apoptosis in hepatocellular carcinoma cells in vitro and in vivo.
    Cho SJ, Lee SS, Kim YJ, Park BD, Choi JS, Liu L, Ham YM, Moon Kim B, Lee SK.
    Cancer Lett; 2010 Jan 28; 287(2):196-206. PubMed ID: 19616371
    [Abstract] [Full Text] [Related]

  • 7. Proliferative suppression by CDK4/6 inhibition: complex function of the retinoblastoma pathway in liver tissue and hepatoma cells.
    Rivadeneira DB, Mayhew CN, Thangavel C, Sotillo E, Reed CA, Graña X, Knudsen ES.
    Gastroenterology; 2010 May 28; 138(5):1920-30. PubMed ID: 20100483
    [Abstract] [Full Text] [Related]

  • 8. Modulation of SIRT3 expression through CDK4/6 enhances the anti-cancer effect of sorafenib in hepatocellular carcinoma cells.
    Jo H, Park Y, Kim T, Kim J, Lee JS, Kim SY, Chung JI, Ko HY, Pyun JC, Kim KS, Lee M, Yun M.
    BMC Cancer; 2020 Apr 19; 20(1):332. PubMed ID: 32306906
    [Abstract] [Full Text] [Related]

  • 9. CDK4/6 inhibitor-SHR6390 exerts potent antitumor activity in esophageal squamous cell carcinoma by inhibiting phosphorylated Rb and inducing G1 cell cycle arrest.
    Wang J, Li Q, Yuan J, Wang J, Chen Z, Liu Z, Li Z, Lai Y, Gao J, Shen L.
    J Transl Med; 2017 Jun 02; 15(1):127. PubMed ID: 28578693
    [Abstract] [Full Text] [Related]

  • 10. Caffeine enhances the anti-tumor effect of 5-fluorouracil via increasing the production of reactive oxygen species in hepatocellular carcinoma.
    Wang Z, Gu C, Wang X, Lang Y, Wu Y, Wu X, Zhu X, Wang K, Yang H.
    Med Oncol; 2019 Oct 29; 36(12):97. PubMed ID: 31664534
    [Abstract] [Full Text] [Related]

  • 11. Treatment of Retinoblastoma 1-Intact Hepatocellular Carcinoma With Cyclin-Dependent Kinase 4/6 Inhibitor Combination Therapy.
    Sheng J, Kohno S, Okada N, Okahashi N, Teranishi K, Matsuda F, Shimizu H, Linn P, Nagatani N, Yamamura M, Harada K, Horike SI, Inoue H, Yano S, Kumar S, Kitajima S, Ajioka I, Takahashi C.
    Hepatology; 2021 Oct 29; 74(4):1971-1993. PubMed ID: 33931882
    [Abstract] [Full Text] [Related]

  • 12. Bafilomycin C1 induces G0/G1 cell-cycle arrest and mitochondrial-mediated apoptosis in human hepatocellular cancer SMMC7721 cells.
    Gao X, Han L, Ding N, Mu Y, Guan P, Hu C, Huang X.
    J Antibiot (Tokyo); 2018 Sep 29; 71(9):808-817. PubMed ID: 29752478
    [Abstract] [Full Text] [Related]

  • 13. The monoclonal antibody CH12 augments 5-fluorouracil-induced growth suppression of hepatocellular carcinoma xenografts expressing epidermal growth factor receptor variant III.
    Jiang H, Dong Q, Luo X, Shi B, Wang H, Gao H, Kong J, Zhang J, Li Z.
    Cancer Lett; 2014 Jan 01; 342(1):113-20. PubMed ID: 24007863
    [Abstract] [Full Text] [Related]

  • 14. Dual cyclin-dependent kinase 4/6 inhibition by PD-0332991 induces apoptosis and senescence in oesophageal squamous cell carcinoma cells.
    Chen L, Pan J.
    Br J Pharmacol; 2017 Aug 01; 174(15):2427-2443. PubMed ID: 28444744
    [Abstract] [Full Text] [Related]

  • 15. PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity.
    Logan JE, Mostofizadeh N, Desai AJ, VON Euw E, Conklin D, Konkankit V, Hamidi H, Eckardt M, Anderson L, Chen HW, Ginther C, Taschereau E, Bui PH, Christensen JG, Belldegrun AS, Slamon DJ, Kabbinavar FF.
    Anticancer Res; 2013 Aug 01; 33(8):2997-3004. PubMed ID: 23898052
    [Abstract] [Full Text] [Related]

  • 16. A network pharmacology approach to investigate the anticancer mechanism of cinobufagin against hepatocellular carcinoma via downregulation of EGFR-CDK2 signaling.
    Yang AL, Wu Q, Hu ZD, Wang SP, Tao YF, Wang AM, Sun YX, Li XL, Dai L, Zhang J.
    Toxicol Appl Pharmacol; 2021 Nov 15; 431():115739. PubMed ID: 34619160
    [Abstract] [Full Text] [Related]

  • 17. Dual Inhibition of Cdc7 and Cdk9 by PHA-767491 Suppresses Hepatocarcinoma Synergistically with 5-Fluorouracil.
    Li W, Zhao XL, Shang SQ, Shen HQ, Chen X.
    Curr Cancer Drug Targets; 2015 Nov 15; 15(3):196-204. PubMed ID: 25643258
    [Abstract] [Full Text] [Related]

  • 18. LncRNA TROJAN promotes proliferation and resistance to CDK4/6 inhibitor via CDK2 transcriptional activation in ER+ breast cancer.
    Jin X, Ge LP, Li DQ, Shao ZM, Di GH, Xu XE, Jiang YZ.
    Mol Cancer; 2020 May 11; 19(1):87. PubMed ID: 32393270
    [Abstract] [Full Text] [Related]

  • 19. Discovery of rafoxanide as a dual CDK4/6 inhibitor for the treatment of skin cancer.
    Shi X, Li H, Shi A, Yao H, Ke K, Dong C, Zhu Y, Qin Y, Ding Y, He YH, Liu X, Li L, Lei L, Hai Q, Chen W, Leung KS, Wong MH, Kung HF, Lin MC.
    Oncol Rep; 2018 Sep 11; 40(3):1592-1600. PubMed ID: 29956794
    [Abstract] [Full Text] [Related]

  • 20. Hemistepsin A Inhibits Cell Proliferation and Induces G0/G1-Phase Arrest, Cellular Senescence and Apoptosis Via the AMPK and p53/p21 Signals in Human Hepatocellular Carcinoma.
    Baek SY, Hwang UW, Suk HY, Kim YW.
    Biomolecules; 2020 May 04; 10(5):. PubMed ID: 32375410
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.